SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH Day	Month	Year	2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET Day	Month	Year
PRIVACY	GUATEMALA		PRIVACY		62 Years	Female	98.00 kg			2021

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)

Cholesterol problems [Blood cholesterol abnormal]
Anaemia [Anaemia]
Took 2 tablets daily of PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 by medical prescription [Prescribed overdose]
Hunger has subsided considerably [Appetite lost]
Diagnostic of goiter 2 [Goiter]
Pylori bacter [Bacterial infection due to helicobacter pylori (H. pylori)]
Bleeding sore in her esophagus [Sore oesophagus]
Legs pain [Leg pain]

(Continued on Additional Information Page)

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
- ☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
- ☐ LIFE THREATENING
- ☐ CONGENITAL ANOMALY
- ☐ OTHER

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name)
#1) PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 (PERINDOPRIL ARGININE 10 mg, INDAPAMIDE 2.5 mg,
#2) DIAMICRON MR 60 mg (GLICLAZIDE) Modified-release tablet, 60 mg **(Continued on Additional Information Page)**

20. DID REACTION ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☒ NA

15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION
#1) 20 mg, qd	#1) Oral use
#2) 60 mg, qd	#2) Oral use

17. INDICATION(S) FOR USE
#1) Hypertension (Hypertension)
#2) Diabetes (Diabetes mellitus)

21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ☐ YES ☐ NO ☒ NA

18. THERAPY DATES(from/to)	19. THERAPY DURATION
#1) 2023 / Ongoing	#1) Unknown
#2) 2021 / Unknown	#2) Unknown

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)
#1) Finerenone (Finerenone) ; 2021 / Ongoing
#2) Nebilet (Nebivolol hydrochloride) ; 2021 / Ongoing
#3) Cardioaspirina (Acetylsalicylic acid) ; 2021 / Ongoing
#4) Hydrapres (Hydralazine hydrochloride) ; 2021 / Unknown
#5) Trulicity (Dulaglutide) ; 2021 / Ongoing
#6) Xigduo (Dapagliflozin propanediol monohydrate, Metformin hydrochloride) ; 2021 / Ongoing **(Continued on Additional Information Page)**

23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

From/To Dates	Type of History / Notes	Description
1993 to Ongoing	Historical Condition	Hypertension (Hypertension)
2015 to Ongoing	Historical Condition	Diabetes (Diabetes mellitus)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER
SERVIER CENTRO AMERICA Y CARIBE
PANAMA

26. REMARKS
Patient ID: 1589343340101
Study ID: IC4-06593-001-GTM*

24b. MFR CONTROL NO.
S25004059

25b. NAME AND ADDRESS OF REPORTER
NAME AND ADDRESS WITHHELD.

24c. DATE RECEIVED BY MANUFACTURER
28-APR-2025

24d. REPORT SOURCE
☒ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL ☐ OTHER:

DATE OF THIS REPORT
07-MAY-2025

25a. REPORT TYPE
☐ INITIAL ☒ FOLLOWUP: 1

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Cholesterol increased [Blood cholesterol increased]

Case Description: This solicited case was received from Patient in GUATEMALA. It is related to protocol number IC4-06593-001-GTM.

The patient was a 62-years-old female (weight: 98 kg, height: 170 cm) (patient ID: 1589343340101) with medical history of Hypertension since unknown date in 1993, was treated with PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 (1 DF daily, orally) from unknown date in 2022 to unknown date and then (2 DF daily) since unknown date in 2023 and Nebivolol hydrochloride (5 mg daily) since unknown date in 2021, Diabetes since unknown date in 2015 was treated with DIAMICRON MR 60 mg (60 mg daily, orally), Dulaglutide (1 DF weekly, subcutaneously) and Dapagliflozin propanediol monohydrate, Metformin hydrochloride (1 DF daily, orally), all since unknown date in 2021, Neuropathy since unknown date, was treated with Atorvastatin (20 mg at unknown daily dose) since unknown date in 2021 and Gabexate (75 mg daily, orally) since unknown date, Cholesterol problems since unknown date in 2021, was treated with Febuxostat (40 mg daily, orally) since unknown date in 2021 to unknown date in JAN-2025 and (80 mg daily, orally) since an unknown date in JAN-2025, Heart problems since an unknown date, treated with Acetylsalicylic acid (unknown daily dose) since unknown date in 2021, Goiter 1 since an unknown date

Other co-suspect included DAFLON 1000 (1000 mg daily, orally) since unknown date in 2021 for unknown indication. Historical drug included covid-19 injection

Concomitant medication included Finerenone (20 mg daily, orally) since unknown date in 2021, Hydralazine hydrochloride (50 mg daily, orally) since unknown date in 2021 all for unknown indication.

On an unknown date in 2021, Patient experienced Cholesterol problems.

Since an unknown date in 2023, the patient experienced overdose, she took 2 tablets daily of PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 by medical prescription.

On an unknown date in Jan-2025, the patient experienced Anaemia.

The patient was treated with Cilostal Xr (100 mg daily), Ferrun hause mann (unknown daily dose), Mag 2 (unknown daily dose) and Eritroproyectina (4000 IU daily, subcutaneously), all since unknown date in JAN-2025 as corrective treatment.

Intensity of the event cholesterol problems not provided. Patient did not know if the event occurred before or after DIAMICRON and DAFLON

Since an unknown date in 2024, her hunger has subsided considerably. It could have been the drug Trulicity, as her doctor told her it could relieve it, but she wasn't sure.

On an unknown date in 2024, the patient was diagnosed with goiter 2, Pylori bacter, which she has already recovered from. She did not associate it with the Servier medications, but she didn't know what it was related to and bleeding sore in her esophagus, which she no longer has.

On an unknown date in NOV-2024, the patient had a venous doppler for legs pain that she still had, which she related to diabetes

On an unknown date in Jan-2025, the patient's cholesterol increased. Treatment of the reaction Cholesterol increase: doctor recommended that she switch from half a tablet of Goturic 80 mg to one full tablet daily.

Patient still had anemia, although tests had not yet been performed. Intensity of the condition and cause of the event were unknown. Treatment of the reaction Anemia: the doctor only prescribed injections and iron (unspecified).

Action taken with PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34, DIAMICRON MR 60 mg and DAFLON 1000: Dose not changed, For DAFLON 1000: Unknown.

Outcome: Recovered for She took 2 tablets daily of PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 by medical prescription (special situation), Pylori Bacter and bleeding sore. Not recovered for Anaemia, Cholesterol problems, Hunger has subsided considerably, cholesterol problems increased, Goiter 2 diagnosed and legs pain

Reporter’s causality assessment: Cholesterol problems, Anaemia, lack of appetite, cholesterol increased, diagnostic of goiter 2, bleeding sore in the oesophagus are not reported.
Legs pain and pylori bacter not related. None of the events were reported as serious.

SIGNIFICANT FOLLOW-UP INFORMATION RECEIVED (28-Apr-2025): Relevant medical history, Lab data was added, Product information regarding concomitant products were updated, new events were added, causality assessment was updated and narrative

Mfr. Control Number: S25004059

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

updated accordingly.

Case Comment: Anaemia is listed as per RSI of DIAMICRON, while other events are unlisted. All events are unlisted as per RSI of PERINDOPRIL ARGININE 10 mg, INDAPAMIDE 2.5 mg, AMLODIPINE 10 mg and DAFLON. Given the nature of events, the confounding factor of underlying diseases and multiple concomitant medication, onset latency with missing information on medical context, circumstances and etiological investigations, the causal role appears to be unlikely.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1	JAN-2025	Blood cholesterol increased		
2	NOV-2024	Ultrasound Doppler Unknown		

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 (PERINDOPRIL ARGININE 10 mg, INDAPAMIDE 2.5 mg, AMLODIPINE 10 mg) Tablet, 10/2.5/10 mg; Regimen #1	20 mg, qd; Oral use	Hypertension (Hypertension)	2023 / Ongoing; Unknown
#1) PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 (PERINDOPRIL ARGININE 10 mg, INDAPAMIDE 2.5 mg, AMLODIPINE 10 mg) Tablet, 10/2.5/10 mg; Regimen #2	10 mg, qd; Oral use	Hypertension (Hypertension)	2022 / Unknown; Unknown
#3) DAFLON 1000 (PURIFIED FLAVONOID FRACTION 1000 mg) Film-coated tablet, 1000 mg; Regimen #1	1000 mg, qd; Oral use	(Product used for unknown indication)	2021 / Ongoing; Unknown

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION continued

#7) Atorvastatin (Atorvastatin) ; 2021 / Ongoing

#8) Goturic (Febuxostat) ; 2021 / Ongoing

#9) Gabexate (Gabexate) ; Ongoing

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Historical Condition	Neuropathy (Neuropathy peripheral);
2021 to Ongoing	Historical Condition	Blood cholesterol abnormal (Blood cholesterol abnormal);
Unknown to Ongoing	Historical Condition	Heart disease, unspecified (Cardiac disorder);
Unknown to Ongoing	Historical Condition	Goiter (Goitre);
Unknown	Historical Drug	Covid-19 injection (COVID-19 vaccine);